These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
487 related articles for article (PubMed ID: 16282729)
1. [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment]. Ishida H; Shirakawa K; Ohsawa T; Sobajima J; Hayashi Y; Nakada H; Yokoyama M; Hashimoto D Gan To Kagaku Ryoho; 2005 Nov; 32(12):1929-34. PubMed ID: 16282729 [TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Fukui Y; Oka T; Nagayama S; Danenberg PV; Danenberg KD; Fukushima M Int J Mol Med; 2008 Dec; 22(6):709-16. PubMed ID: 19020767 [TBL] [Abstract][Full Text] [Related]
3. Correlations of clinicopathological factors with protein expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in colorectal cancer. Sumi T; Katsumata K; Tsuchida A; Ishizaki T; Shimazu M; Aoki T Chemotherapy; 2010; 56(2):120-6. PubMed ID: 20407238 [TBL] [Abstract][Full Text] [Related]
4. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase]. Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Yamada H; Iinuma H; Watanabe T Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408 [TBL] [Abstract][Full Text] [Related]
6. [Expression of mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in diffusely infiltrating colorectal cancer]. Ishibashi K; Sobajima J; Ohsawa T; Yokoyama M; Miyazaki T; Nakada H; Gonda T; Ishida H Gan To Kagaku Ryoho; 2007 Jul; 34(7):1073-7. PubMed ID: 17637543 [TBL] [Abstract][Full Text] [Related]
7. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy. Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211 [TBL] [Abstract][Full Text] [Related]
8. TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy. Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Inoue Y; Kobayashi M; Miki C; Kusunoki M J Surg Oncol; 2012 May; 105(6):529-34. PubMed ID: 22006578 [TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634 [TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1. Harada K; Kawashima Y; Yoshida H; Sato M Oncol Rep; 2006 Jun; 15(6):1417-23. PubMed ID: 16685374 [TBL] [Abstract][Full Text] [Related]
11. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451 [TBL] [Abstract][Full Text] [Related]
12. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens. Kai K; Kitajima Y; Hiraki M; Satoh S; Tanaka M; Nakafusa Y; Tokunaga O; Miyazaki K Cancer Lett; 2007 Dec; 258(1):45-54. PubMed ID: 17892912 [TBL] [Abstract][Full Text] [Related]
13. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C Oncology; 2006; 70(5):366-77. PubMed ID: 17179731 [TBL] [Abstract][Full Text] [Related]
14. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Kaira K; Serizawa M; Koh Y; Miura S; Kaira R; Abe M; Nakagawa K; Ohde Y; Okumura T; Murakami H; Tsuya A; Nakamura Y; Naito T; Takahashi T; Kondo H; Nakajima T; Endo M; Yamamoto N Lung Cancer; 2011 Dec; 74(3):419-25. PubMed ID: 21550686 [TBL] [Abstract][Full Text] [Related]
15. Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma. Nagasaki T; Tsuchiya T; Tagawa T; Honda S; Yamasaki N; Miyazaki T; Hidaka S; Hayashi T; Nagayasu T Clin Lung Cancer; 2010 Nov; 11(6):412-22. PubMed ID: 21062732 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Kamoshida S; Shiogama K; Shimomura R; Inada K; Sakurai Y; Ochiai M; Matuoka H; Maeda K; Tsutsumi Y Oncol Rep; 2005 Nov; 14(5):1223-30. PubMed ID: 16211289 [TBL] [Abstract][Full Text] [Related]
17. [Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer]. Yamada T; Tanaka N; Yokoi K; Ishikawa N; Seya T; Horiba K; Kanazawa Y; Shirakawa T; Ohkawa K; Kudoh H; Koizumi M; Yoshioka M; Shinji S; Yamashita K; Tajiri T Gan To Kagaku Ryoho; 2006 Nov; 33(11):1603-9. PubMed ID: 17108726 [TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739 [TBL] [Abstract][Full Text] [Related]
19. [Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer]. Ochiai T; Sugitani M; Nishimura K; Noguchi H; Watanabe T; Sengoku H; Komiyama H; Okano M Gan To Kagaku Ryoho; 2002 Mar; 29(3):413-20. PubMed ID: 11915731 [TBL] [Abstract][Full Text] [Related]
20. Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Inokuchi M; Uetake H; Shirota Y; Yamada H; Tajima M; Sugihara K Cancer Chemother Pharmacol; 2004 May; 53(5):391-6. PubMed ID: 15060742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]